Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results (Showing 1 to 20 of 24)As of 10-Feb-2010
New Screen 

All Reports | Brokerage Reports | Independent Reports
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
1-Feb-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDZenpep Tracker: Week ending 1/22/201010$254 Stars 4 Stars View Abstract
1-Feb-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDTable is set for a strong 2010 for WCRX8$254 Stars 4 Stars View Abstract
29-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDFirmenich To Develop S6973­-A Sweet Result For Senomyx4$104 Stars 4 Stars View Abstract
29-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDZenpep Tracker: Week ending 1/15/201010$254 Stars 4 Stars View Abstract
28-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDRaising Price Target On NeurogesX As Qutenza Launch Approaches7$254 Stars 4 Stars View Abstract
25-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDProlor Presents Positive Preclinical Pharmacokinetic Primate IFN Data4$10 4 Stars View Abstract
25-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDPhase 2 Clinical Data On Diabetes Drug Looks Promising4$10 4 Stars View Abstract
21-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDPharmasset to Develop Optically Pure Version Of PSI-78514$104 Stars 4 Stars View Abstract
21-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDCLDA Update, Raising PT To $288$254 Stars 4 Stars View Abstract
20-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDPublic Citizen highlights "known" risks with Savella5$104 Stars 4 Stars View Abstract
20-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDRoche Invests Further $180 Million In Enhanze Delivery Device4$104 Stars 4 Stars View Abstract
19-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDZenpep Tracker: Week ending 1/8/201010$254 Stars 4 Stars View Abstract
19-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDRaising Price Target After Chatting With Chelsea6$254 Stars 4 Stars View Abstract
14-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDZenpep Tracker: Week ending 1/1/2010 (slow start)10$254 Stars 4 Stars View Abstract
8-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDKrystexxa BLA On Track, Resubmission Expected In Q14$10 4 Stars View Abstract
8-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDMRX: Solodyn Tracker - Week ending 12/25/2009 (micro positive/macro negative)10$254 Stars 4 Stars View Abstract
6-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDAmifampridine Approved In Europe As Expected4$104 Stars 4 Stars View Abstract
5-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDApriso Tracker: Week ending 12/25/2009 (Momentum building)9$254 Stars 4 Stars View Abstract
5-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDUpping #'s to reflect pricing power in HE12$254 Stars 4 Stars View Abstract
4-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDZenpep Tracker: Week ending 12/25/2009 (holiday noise)10$254 Stars 4 Stars View Abstract
Next 4

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.